Which has stronger valuation and earnings, PLYX or KYNB?

Kyntra Bio has higher revenue and earnings than Polaryx Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polaryx Therapeutics N/A N/A N/A N/A N/A Kyntra Bio $6.44M 4.48 $183.45M $40.46 0.18

Is PLYX or KYNB more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Polaryx Therapeutics' net margin of 0.00%. Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A Kyntra Bio 2,199.13% N/A -36.71%

Do analysts prefer KYNB or AADI?

Kyntra Bio presently has a consensus target price of $30.00, indicating a potential upside of 320.76%. Given Kyntra Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Kyntra Bio is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media prefer PYXS or KYNB?

In the previous week, Kyntra Bio had 3 more articles in the media than Pyxis Oncology. MarketBeat recorded 5 mentions for Kyntra Bio and 2 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 1.68 beat Kyntra Bio's score of 0.70 indicating that Pyxis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Kyntra Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KYNB or ALDX?

In the previous week, Kyntra Bio had 2 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 5 mentions for Kyntra Bio and 3 mentions for Aldeyra Therapeutics. Kyntra Bio's average media sentiment score of 0.70 beat Aldeyra Therapeutics' score of 0.47 indicating that Kyntra Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyntra Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aldeyra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CRDF or KYNB?

In the previous week, Kyntra Bio had 3 more articles in the media than Cardiff Oncology. MarketBeat recorded 5 mentions for Kyntra Bio and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 1.89 beat Kyntra Bio's score of 0.70 indicating that Cardiff Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Kyntra Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Kyntra Bio (KYNB) Competitors

$7.13 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$7.04 -0.09 (-1.26%)

As of 06/12/2026 07:26 PM Eastern

Compare

KYNB vs. PLYX, AADI, PYXS, ALDX, and CRDF

Should you buy Kyntra Bio stock or one of its competitors? MarketBeat compares Kyntra Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kyntra Bio include Polaryx Therapeutics (PLYX), Aadi Bioscience (AADI), Pyxis Oncology (PYXS), Aldeyra Therapeutics (ALDX), and Cardiff Oncology (CRDF). These companies are all part of the "pharmaceutical products" industry.

How does Kyntra Bio compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Kyntra Bio (NASDAQ:KYNB) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

72.7% of Kyntra Bio shares are owned by institutional investors. 4.2% of Kyntra Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Kyntra Bio has a net margin of 2,199.13% compared to Polaryx Therapeutics' net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Kyntra Bio	2,199.13%	N/A	-36.71%

Kyntra Bio has higher revenue and earnings than Polaryx Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A
Kyntra Bio	$6.44M	4.48	$183.45M	$40.46	0.18

In the previous week, Kyntra Bio had 3 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 5 mentions for Kyntra Bio and 2 mentions for Polaryx Therapeutics. Kyntra Bio's average media sentiment score of 0.70 beat Polaryx Therapeutics' score of 0.44 indicating that Kyntra Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Polaryx Therapeutics	Neutral
Kyntra Bio	Positive

Polaryx Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 321.94%. Kyntra Bio has a consensus price target of $30.00, suggesting a potential upside of 320.76%. Given Polaryx Therapeutics' higher possible upside, research analysts plainly believe Polaryx Therapeutics is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Kyntra Bio beats Polaryx Therapeutics on 8 of the 10 factors compared between the two stocks.

How does Kyntra Bio compare to Aadi Bioscience?

Kyntra Bio (NASDAQ:KYNB) and Aadi Bioscience (NASDAQ:AADI) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.

In the previous week, Kyntra Bio had 5 more articles in the media than Aadi Bioscience. MarketBeat recorded 5 mentions for Kyntra Bio and 0 mentions for Aadi Bioscience. Kyntra Bio's average media sentiment score of 0.70 beat Aadi Bioscience's score of 0.00 indicating that Kyntra Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Kyntra Bio	Positive
Aadi Bioscience	Neutral

Kyntra Bio has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

Kyntra Bio has a net margin of 2,199.13% compared to Aadi Bioscience's net margin of -246.06%. Kyntra Bio's return on equity of 0.00% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-36.71%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Kyntra Bio has higher earnings, but lower revenue than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	4.48	$183.45M	$40.46	0.18
Aadi Bioscience	$25.07M	4.10	-$65.76M	-$2.35	N/A

72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 4.2% of Kyntra Bio shares are owned by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kyntra Bio presently has a consensus target price of $30.00, indicating a potential upside of 320.76%. Given Kyntra Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Kyntra Bio is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Kyntra Bio beats Aadi Bioscience on 15 of the 17 factors compared between the two stocks.

How does Kyntra Bio compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and Kyntra Bio (NASDAQ:KYNB) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

In the previous week, Kyntra Bio had 3 more articles in the media than Pyxis Oncology. MarketBeat recorded 5 mentions for Kyntra Bio and 2 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 1.68 beat Kyntra Bio's score of 0.70 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Kyntra Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pyxis Oncology has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market.

39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by company insiders. Comparatively, 4.2% of Kyntra Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Kyntra Bio has lower revenue, but higher earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	8.04	-$79.62M	-$1.31	N/A
Kyntra Bio	$6.44M	4.48	$183.45M	$40.46	0.18

Pyxis Oncology presently has a consensus price target of $6.83, indicating a potential upside of 288.26%. Kyntra Bio has a consensus price target of $30.00, indicating a potential upside of 320.76%. Given Kyntra Bio's higher probable upside, analysts plainly believe Kyntra Bio is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Kyntra Bio has a net margin of 2,199.13% compared to Pyxis Oncology's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Kyntra Bio	2,199.13%	N/A	-36.71%

Summary

Kyntra Bio beats Pyxis Oncology on 10 of the 17 factors compared between the two stocks.

How does Kyntra Bio compare to Aldeyra Therapeutics?

Kyntra Bio (NASDAQ:KYNB) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Kyntra Bio presently has a consensus target price of $30.00, indicating a potential upside of 320.76%. Aldeyra Therapeutics has a consensus target price of $5.50, indicating a potential upside of 212.50%. Given Kyntra Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Kyntra Bio is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Kyntra Bio had 2 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 5 mentions for Kyntra Bio and 3 mentions for Aldeyra Therapeutics. Kyntra Bio's average media sentiment score of 0.70 beat Aldeyra Therapeutics' score of 0.47 indicating that Kyntra Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aldeyra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 4.2% of Kyntra Bio shares are owned by company insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Kyntra Bio has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	4.48	$183.45M	$40.46	0.18
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A

Kyntra Bio has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market.

Kyntra Bio has a net margin of 2,199.13% compared to Aldeyra Therapeutics' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-36.71%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

Summary

Kyntra Bio beats Aldeyra Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Kyntra Bio compare to Cardiff Oncology?

Cardiff Oncology (NASDAQ:CRDF) and Kyntra Bio (NASDAQ:KYNB) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

Kyntra Bio has a net margin of 2,199.13% compared to Cardiff Oncology's net margin of -8,527.43%. Kyntra Bio's return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%
Kyntra Bio	2,199.13%	N/A	-36.71%

In the previous week, Kyntra Bio had 3 more articles in the media than Cardiff Oncology. MarketBeat recorded 5 mentions for Kyntra Bio and 2 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 1.89 beat Kyntra Bio's score of 0.70 indicating that Cardiff Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Kyntra Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kyntra Bio has higher revenue and earnings than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	178.46	-$45.85M	-$0.67	N/A
Kyntra Bio	$6.44M	4.48	$183.45M	$40.46	0.18

Cardiff Oncology presently has a consensus target price of $8.75, indicating a potential upside of 468.18%. Kyntra Bio has a consensus target price of $30.00, indicating a potential upside of 320.76%. Given Cardiff Oncology's higher probable upside, equities analysts plainly believe Cardiff Oncology is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are owned by institutional investors. 8.5% of Cardiff Oncology shares are owned by company insiders. Comparatively, 4.2% of Kyntra Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cardiff Oncology has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

Summary

Kyntra Bio beats Cardiff Oncology on 11 of the 17 factors compared between the two stocks.

Get Kyntra Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KYNB vs. The Competition

Export

Metric	Kyntra Bio	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$28.88M	$979.54M	$4.29B	$12.05B
Dividend Yield	N/A	4.84%	10.25%	5.66%
P/E Ratio	0.18	1.45	22.29	24.42
Price / Sales	4.48	120.49	159.54	111.24
Price / Cash	N/A	20.06	40.19	37.92
Price / Book	-1.70	7.85	26.92	6.82
Net Income	$183.45M	-$4.88M	$116.61M	$337.56M
7 Day Performance	7.54%	0.64%	0.25%	1.17%
1 Month Performance	4.55%	-0.16%	0.25%	3.16%
1 Year Performance	N/A	47.51%	14.25%	30.58%

Kyntra Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KYNB Kyntra Bio	3.1587 of 5 stars	$7.13 flat	$30.00 +320.8%	N/A	$28.88M	$6.44M	0.18	570	Gap Down High Trading Volume
PLYX Polaryx Therapeutics	4.0526 of 5 stars	$2.33 -7.9%	$10.00 +329.2%	N/A	$109.58M	N/A	N/A	11	Short Interest Increase Gap Up
AADI Aadi Bioscience	N/A	$4.40 +1.4%	N/A	+112.2%	$108.67M	$25.07M	N/A	40
PYXS Pyxis Oncology	3.6362 of 5 stars	$1.78 +4.1%	$6.83 +283.9%	+46.7%	$108.34M	$13.86M	N/A	60	Gap Up
ALDX Aldeyra Therapeutics	3.2829 of 5 stars	$1.63 -7.4%	$5.50 +237.4%	-36.7%	$106.17M	N/A	N/A	10	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KYNB) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kyntra Bio (KYNB) Competitors

KYNB vs. PLYX, AADI, PYXS, ALDX, and CRDF

How does Kyntra Bio compare to Polaryx Therapeutics?

Summary

How does Kyntra Bio compare to Aadi Bioscience?

Summary

How does Kyntra Bio compare to Pyxis Oncology?

Summary

How does Kyntra Bio compare to Aldeyra Therapeutics?

Summary

How does Kyntra Bio compare to Cardiff Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYNB vs. The Competition

Kyntra Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kyntra Bio (KYNB) Competitors

KYNB vs. PLYX, AADI, PYXS, ALDX, and CRDF

How does Kyntra Bio compare to Polaryx Therapeutics?

Do institutionals and insiders hold more shares of PLYX or KYNB?

Is PLYX or KYNB more profitable?

Which has stronger valuation and earnings, PLYX or KYNB?

Does the media refer more to PLYX or KYNB?

Do analysts recommend PLYX or KYNB?

Summary

How does Kyntra Bio compare to Aadi Bioscience?

Does the media prefer KYNB or AADI?

Which has more risk and volatility, KYNB or AADI?

Is KYNB or AADI more profitable?

Which has higher valuation & earnings, KYNB or AADI?

Do institutionals & insiders have more ownership in KYNB or AADI?

Do analysts prefer KYNB or AADI?

Summary

How does Kyntra Bio compare to Pyxis Oncology?

Does the media prefer PYXS or KYNB?

Which has more risk and volatility, PYXS or KYNB?

Do insiders & institutionals have more ownership in PYXS or KYNB?

Which has stronger valuation & earnings, PYXS or KYNB?

Do analysts recommend PYXS or KYNB?

Is PYXS or KYNB more profitable?

Summary

How does Kyntra Bio compare to Aldeyra Therapeutics?

Do analysts rate KYNB or ALDX?

Does the media prefer KYNB or ALDX?

Do insiders and institutionals have more ownership in KYNB or ALDX?

Which has better valuation and earnings, KYNB or ALDX?

Which has more volatility & risk, KYNB or ALDX?

Is KYNB or ALDX more profitable?

Summary

How does Kyntra Bio compare to Cardiff Oncology?

Is CRDF or KYNB more profitable?

Does the media favor CRDF or KYNB?

Which has stronger valuation and earnings, CRDF or KYNB?

Do analysts rate CRDF or KYNB?

Do institutionals & insiders have more ownership in CRDF or KYNB?

Which has more volatility & risk, CRDF or KYNB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYNB vs. The Competition

Kyntra Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools